Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company’s lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.

Clinical Trial Results Overview

Drug Profile & Technology

ADC Architecture

• Target: B7-H3 – tumor-associated antigen overexpressed across multiple solid tumors
• Antibody Component: Fully human anti-B7-H3 monoclonal antibody
• Payload: Topoisomerase inhibitor (TOPOi) covalently linked via proprietary conjugation technology
• Development Status: Independently developed by Hansoh Pharmaceutical with global intellectual property

Mechanism of Action

• Targeted Delivery: Antibody directs cytotoxic payload specifically to B7-H3-expressing tumor cells
• Bystander Effect: Payload diffusion may kill adjacent tumor cells regardless of B7-H3 expression
• Therapeutic Rationale: Exploits high B7-H3 expression in osteosarcoma and other solid tumors while sparing normal tissues

Global Development Portfolio

China Development Pipeline

• Phase III: Osteosarcoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC)
• Proof-of-Concept Studies: Head and neck cancer, prostate cancer, esophageal squamous cell carcinoma, colorectal cancer, and other solid tumors
• Strategic Focus: Leveraging B7-H3’s broad expression profile across multiple tumor types

Global Partnership with GSK

• Deal Structure: Exclusive worldwide license granted to GlaxoSmithKline (GSK) in December 2023
• Territory: Worldwide excluding Mainland China, Hong Kong, Macau, and Taiwan
• Financial Terms: Up to $1.7 billion in upfront, milestone, and royalty payments
• Strategic Value: Validates Hansoh’s ADC platform and provides non-dilutive funding for China development

Market Implications

Osteosarcoma Treatment Landscape

• Unmet Need: Limited effective options for relapsed/refractory osteosarcoma with poor prognosis
• Patient Population: Approximately 1,000 new osteosarcoma cases annually in the US, with higher burden globally
• Current Standard: Multi-agent chemotherapy with modest efficacy and significant toxicity
• Commercial Opportunity: First-in-class B7-H3 ADC could capture significant market share in orphan indication

ADC Competitive Positioning

• Target Differentiation: B7-H3 represents emerging target with favorable safety profile compared to traditional ADC targets
• Payload Advantage: Topoisomerase inhibitor payload offers proven cytotoxic mechanism with manageable toxicity
• Platform Validation: Success validates Hansoh’s internal ADC discovery and development capabilities
• Pipeline Leverage: Positive osteosarcoma data de-risks development in larger indications like NSCLC and SCLC

Strategic Outlook

The positive Phase III results position Hansoh to:

• Accelerate regulatory filings for osteosarcoma indication in China
• Support GSK’s global development strategy with robust clinical data package
• Expand proof-of-concept studies into additional B7-H3-expressing tumor types
• Enhance valuation of remaining China rights ahead of potential commercial launch

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and partnership outcomes. Actual results may differ due to regulatory decisions, competitive developments, and clinical trial variability.-Fineline Info & Tech